Alternatives to Schrodinger

AI-driven drug discovery platform combining 50+ PB of proprietary data with automated wet labs to design and validate optimized molecules.

Open-source AI drug discovery assistant for molecular research

AI-native drug discovery: phenomics, robotics, and a 50+ petabyte dataset to de-risk medicines.

Tech-driven drug discovery and biologics manufacturing platform

Highly selective small-molecule drug discovery for oncology, immunology, and metabolic diseases.

End-to-end generative AI drug discovery platform from target ID to clinical trials, validated by a Phase III pipeline.

All-in-human AI foundation models for precision neurology and CNS drug discovery

Generative AI and robotics for autonomous drug discovery, compressing the DMTA cycle to under two years.

AI drug discovery knowledge graph for target identification and drug repurposing.

AI-native drug discovery platform turning 50+ PB of cellular imaging data into clinical-stage therapies

AI co-scientist for biomedical research: multi-omics, drug discovery, and lab protocol reasoning

AI-driven CRISPR platform revealing causal disease-driving RNA pathways for immunology and oncology drug discovery

AI platform for genomic medicine molecular construct design

AI-designed multivalent nanoparticles for cell-selective drug delivery

Mechanistic interpretability platform to understand, debug, and design AI models

FDA-cleared AI for cancer pathology diagnostics and biomarker discovery.

AI-powered precision oncology platform analyzing clinical and molecular data for personalized cancer care.

Enterprise AI pathology platform for diagnostics and drug development.

Automated cloud lab to validate protein designs in under 3 weeks.

AI scientist delivering defendable drug program decisions in 2–5 days.

AI foundation models predicting patient drug response to de-risk clinical trials

AI target discovery platform for neurotherapeutics across disorders

Evidence-based AI research assistant for life sciences with connected knowledge maps.

AI agents for quantitative clinical trial design and evidence synthesis

AI-driven diagnostics design for biothreats in days

Owkin's K Pro: an autonomous AI scientist for biopharma R&D decision-making

Oncology real-world evidence platform turning patient data into AI-powered insights for cancer research and care.

AI-driven clinical trial patient matching and recruitment from EMR data.

Cloud ELN, LIMS, and AI platform that unifies biotech R&D data.

Regulatory-cleared quantitative imaging biomarkers from MRI, CT, and PET for radiology and biopharma